Stay in Touch
Get sneak previews of special offers & upcoming events delivered to your inbox.
Sign in
03-26-2012 06:35 PM
A monthly injection of an experimental drug made by the US biotech firm Amgen reduced patients' cholesterol by up to 66 percent, according to a small study described at a US cardiology conference.
The early phase 1 clinical trial, designed mainly to see if the treatment was safe, followed 51 patients who received a shot of the drug, AMG 145, either once every two or every four weeks.
Among trial subjects were already taking high doses of cholesterol-lowering drugs, known as statins, and who got the shot every two weeks, the dangerous type of cholesterol (LDL) in their bodies dropped by an average of 63 percent by the eighth week.
And those who were on low doses of statins and received the drug every four weeks saw a slightly higher average drop in LDL cholesterol -- 66 percent by the end of the same time period.
No deaths or adverse events were recorded during the preliminary study, which was presented for the the first time on Sunday at the American College of Cardiology annual conference.
The drug is a fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood.
Article:
http://news.yahoo.com/monthly-shot-lowers-cholesterol-66-percent-study-193641899.html
Get sneak previews of special offers & upcoming events delivered to your inbox.
*You're signing up to receive QVC promotional email.
Find recent orders, do a return or exchange, create a Wish List & more.
Privacy StatementGeneral Terms of Use
QVC is not responsible for the availability, content, security, policies, or practices of the above referenced third-party linked sites nor liable for statements, claims, opinions, or representations contained therein. QVC's Privacy Statement does not apply to these third-party web sites.
© 1995-2024 QVC, Inc. All rights reserved. | QVC, Q and the Q logo are registered service marks of ER Marks, Inc. 888-345-5788